Arcturus Therapeutics, Inc. is an RNA medicines company. Our versatile RNA therapeutics platform enables development of all types of RNA medicines including small interfering RNA (siRNA), messenger RNA (mRNA), antisense RNA, microRNA and gene editing therapeutics.
Our proprietary unlocked nucleomonomer agent (UNA) Oligomer™ technology can be used to target any gene in the human genome, as well the genes of other species, such as viruses, for therapeutic purposes.
Our patented Lipid-enabled and Unlocked Nucleomonomer Agent modified RNA (LUNAR™) nanoparticle delivery system allows safe and efficient in vivo delivery of all RNA medicines.
We use our innovative technologies to develop best-in-class RNA medicines that treat rare diseases. We also collaborate with industry leaders including Janssen Pharmaceuticals, Inc. (a Johnson and Johnson Company) and Ultragenyx Pharmaceutical, Inc. to develop novel RNA therapeutics.
June 1, 2016
Arcturus Therapeutics To Present At 2016 BIO International Convention in San Francisco
March 16, 2016
Arcturus Therapeutics Receives Intent to Grant Notice from the European Patent Office for their Unlocked Nucleomonomer Agent (UNA) Technology
January 6, 2016
Arcturus Therapeutics Selected to Present at Biotech Showcase™ 2016